CHMP positive for Fasenra (benralizumab) extension of indication to treat eosinophilic granulomatosis with polyangiitis (EGPA)
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Fasenra (benralizumab). The marketing authorisation holder for this medicinal product is AstraZeneca AB.
The CHMP adopted an extension to the existing indication as follows: Eosinophilic granulomatosis with polyangiitis (EGPA) . Fasenra is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.